Protecting you from Europe’s most dangerous animal.

Tick-borne diseases are a serious health problem. We develop the world’s first broad spectrum vaccine that can protect against all diseases distributed by tick bites.

A new approach to protect against all Tick-borne diseases

Norden Vaccines is developing a vaccine for humans against ticks (Ixodes spp.), which transmit a variety of different, often very serious diseases. We are circumventing the problems associated with developing individual vaccines against all these pathogens by taking a radically different approach. Instead, we are vaccinating against the carrier of the pathogens, i.e. the tick itself. Instead of fighting pathogens after they have entered our bodies, we prevent this from happening in the first place. To this end, we have identified important antigens in tick saliva and developed formulations that elicit a strong immune response to them. After vaccination, the ticks will be repelled and no pathogens can be transmitted.

"Tick-borne diseases are on the rise and there are no vaccines available against most of them. We will change this by developing one single vaccine that will protect against all of these.”
Prof. Dr. Michael Hust, Co-Founder

Who we are

Our team combines hands-on experience in genetic engineering, vaccine development, immunology and biotechnology. The founders were initially supported by the GoBIO programme of the German Research Minitstry, and are now joined by the experienced clinical development team of Co-Investor and development partner CORAT GmbH.

News

November 3, 2025

Norden Vaccines wins substantial follow up funding from Government

Based on the data from the initial vaccine development program, the Federal Ministry of Research, Technology and Space (BMFTR) granted follow up funding for the further preclinical development and necessary analyses to proceed to clinical studies.

March 25, 2024

CORAT joins the development of tick vaccines as investor and preclinical development partner

CORAT GmbH joined the tick vaccine development project and provides their extensive experience with biological drug production, preclinical and clinical development of biologicals to the program, and Dr. Andreas Herrmann joined Norden Vaccines as CEO. Andreas (co-)founded and headed different biotech companies including Celonic (CMO), Baliopharm (innovator company for autoimmune diseases, oncology), Synimmune (bispecific antibodies, oncology), Leva and Alvotech.

December 1, 2020

DurchSTARTer Prize of the State of lower Saxony

Out of 91 applicant start-ups, Norden Vaccines was selected as one of the three best finalists and won third prize. The DurchSTARTer is an award presented by the state of Lower Saxony that honours the best start-ups in all business areas.

April 9, 2019

Innovation Prize of the German Bioregions

The highly regarded Innovation Prize of the German Bioregions was awarded to the the Norden Vaccines Team at the German Biotechnology Days in Wuerzburg. German Bioregions is the national alliance of 30 German biotech clusters (Bioregions).

August 26, 2018

Norden Vaccines wins substantial Government funding

The Norden Vaccines team was among the winners for financial support by the highly competitive GO-Bio program. The Federal Ministry of Education and Research (BMBF) has launched the ‘Biotechnology Start-up Initiative’ (GO-Bio) to give research teams from the life sciences who are ready to start their own businesses the opportunity to develop technically sophisticated ideas into viable start-ups.

August 8, 2018

Lower Saxony Innovation Award

The Norden Vaccines team was among the finalists of the State of Lower Saxony Innovation award. The picture shows members of the team with the document handed over by the Minister of Science and Research, Björn Thümler (left).